Definitive Healthcare Corp. (DH) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite some positive indicators like increased operating cash flows and improved renewal rates, the overall sentiment is negative due to declining revenue guidance, subscription revenue decline, and management's vague responses on critical renewal issues. The Q&A highlighted budget constraints, particularly in life sciences, and expected gross margin pressure. These factors suggest a challenging environment, likely leading to a negative stock price reaction.
Key Financial Performance
Total Revenue $60 million, down 4% year-over-year. This was driven by another quarter of modest year-over-year improvement in renewal rates.
Adjusted EBITDA $18.9 million, representing a margin of 32%, which was $2 million above the high end of guidance. This reflects continued operational improvements with a focus on maintaining solid expense discipline.
Unlevered Free Cash Flow Approximately $51 million for the trailing 12 months, reflecting strong cash flow generation.
Subscription Revenues $58.2 million, declined 4% year-over-year, reflecting stabilization in absolute dollars quarter-over-quarter and a 2-point trajectory improvement over the subscription growth rate in the prior quarter.
Adjusted Gross Profit $49.4 million, down 4% from Q3 2024, reflecting the revenue decline. Adjusted gross profit margin of 82% was roughly flat from Q3 2024.
Operating Cash Flows $59.2 million on a trailing 12-month basis, up 8% from the comparable period a year ago, benefiting from strong collections and higher deferred revenue.
Deferred Revenue $92 million, up 7% year-over-year, reflecting growth in remaining performance obligations.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New claims data source: Introduced in Q3 to address data disruption in the market segment.
Syndicated go-to-market partnership with LiveRamp: Launched to support customers' ad tech efforts, enabling marketers to self-serve using prebuilt audience segments.
Enterprise customer growth: Enterprise customer count increased by 10 to 520, the highest since Q3 last year.
Agency partnerships: Signed 8 new agencies in Q3 to expand digital engagement.
Revenue: $60 million in Q3, down 4% year-over-year, but at the high end of guidance.
Adjusted EBITDA: $18.9 million, representing a 32% margin, $2 million above guidance.
Retention rates: Improved year-over-year, though durability of the trend is uncertain.
Cost savings: Achieved $2.5 million in Q3 through data contract renegotiation and replacing a disrupted data source.
Differentiated data: Expanded data sets with new sources, including a new claims data source, and plans to add another source to exceed historical data levels.
Seamless integrations: Focused on embedding data into customer workflows, leading to higher retention rates.
Customer success: Enhanced customer engagement processes to improve retention and value delivery.
Digital partnerships and innovation: Progress in ad tech efforts and partnerships, including a significant new strategic partner and expanded agency presence.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Revenue Decline: Total revenue was $60 million, down 4% year-over-year, indicating challenges in maintaining or growing revenue.
Renewal Rates: While there was modest year-over-year improvement in renewal rates, it remains too early to call this trend durable, and the company faces a large renewal cohort in December and January, posing risks to retention.
Data Disruption: The company faced disruptions in the claims data market over the past year, requiring investments in new data sources to address these challenges.
Macroeconomic Environment: The company operates in a dynamic macroeconomic environment, which could impact customer spending and renewal rates.
Retention Rates: Retention rates have shown improvement but are not yet at levels that would enable consistent top-line growth, indicating ongoing challenges in customer retention.
Integration Challenges: Efforts to integrate data into customer systems are critical for retention, but achieving seamless integration remains a challenge.
Competitive Pressures: The company faces competition in providing differentiated data and seamless integrations, which are critical to winning and retaining customers.
Strategic Partnerships: While new partnerships are being developed, they take time to generate revenue, posing a delay in realizing financial benefits.
Customer Success: The company is revisiting its customer engagement process to improve retention and value delivery, indicating current gaps in customer success strategies.
Innovation and Digital Engagement: Investments in innovation and digital engagement are ongoing, but the time required to see returns on these investments could delay financial improvements.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: For Q4 2025, the company expects to deliver $59 million to $60 million in revenue, representing a decrease of 4% to 5% compared to Q4 2024. For the full year 2025, revenue is expected to be $239 million to $240 million, a 5% decline year-over-year.
Profitability Projections: For Q4 2025, adjusted operating income is expected to be $13.5 million to $14.5 million, adjusted EBITDA is projected at $16 million to $17 million (27% to 29% margin), and adjusted net income is forecasted at $8 million to $9 million ($0.05 to $0.06 per diluted share). For the full year 2025, adjusted EBITDA is expected to be $68 million to $69 million (28% to 29% margin), and adjusted net income is projected at $34 million to $35 million ($0.23 to $0.24 per diluted share).
Customer Retention and Growth: The company is cautiously optimistic about improving retention rates but remains cautious about macroeconomic pressures. Efforts to improve customer retention and expand enterprise customer count are ongoing.
Strategic Investments: Planned investments include enhancing data assets, expanding claims data sources, and supporting digital engagement strategies. These investments aim to improve customer retention and drive long-term growth.
Market Trends and Conditions: The company remains cautious about the macroeconomic environment and its impact on renewals and growth. However, it is focused on leveraging its differentiated data and operational strategies to navigate these challenges.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Share Repurchase: Repurchased approximately 2 million shares in the quarter for a total of about $9 million with about $49 million remaining under our authorization.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Are competitive wins more common or are new logos more white space opportunities? What are the biggest reasons for clients switching vendors?
A:Competitive wins and new logos are both significant, with new logos responding quickly to efforts. Key reasons for switching vendors include ease of data integration, leveraging insights, and the accuracy of data.
Q:How strategically important is claims data for product positioning and customer needs? What incremental lift could new claims data sources provide?
A:Claims data is strategically important for product positioning and customer needs. The company has reached parity in claims data availability and is now exceeding historical levels. This data integration is crucial for creating complex data relationships and hierarchies, which are essential for customer use cases.
Q:Have there been any changes in how pharma clients allocate budgets or approach spending due to MFN and tariff policies?
A:No notable changes or tariff-specific impacts have been observed. However, biopharma customers have faced tighter budget constraints over the past year.
Q:Are there updates on improvements in downsell pressure and what is resonating with clients?
A:Downsell pressure remains isolated to the life sciences space. Stabilization in total client count and growth in enterprise customers are encouraging. Renewal rates have improved, and gross dollar retention is expected to increase year-over-year.
Q:What drives end market customers to expand from testing to activation campaigns using Definitive data?
A:The accuracy and veracity of Definitive data allow for better targeting and return on investment. Customers see significant returns, leading to increased commitments. Partnerships with platforms like LiveRamp and Bombora enhance data activation capabilities.
Q:Which verticals are moving faster towards production and activation from pilots when it comes to agencies?
A:No significant differentiation across verticals has been observed. Success has been noted in the diversified space, with opportunities in the life sciences space as well.
Q:How did net new motion perform versus expectations, and where is strength observed between partner/agency ecosystem and direct motion?
A:New logo performance exceeded internal expectations, with broad-based strength across end markets. Acceleration is observed in the direct space, while agency relationships are still developing.
Q:Will adding additional data sources impact gross margin, and what is the outlook for gross margin next year?
A:Adding data sources may create temporary gross margin pressure. Year-over-year margin pressure is expected due to non-repeating credits and top-line pressure.
Q:Are customers staying on but spending less, and what is the future growth algorithm between new customer adds and expansion within existing customers?
A:Customers are staying on but spending less due to budget pressures, particularly in life sciences. Future growth will involve both new customer adds and expansion within existing accounts.
Q:What is the outlook for renewals in December and January, and how will it shape 2026?
A:December and January renewals are critical, making up over 30% of annual renewals. The company is focused on improving renewal rates and addressing cyclical headwinds. Current remaining performance obligations indicate mid-single-digit declines.
Q:What actions are being taken to mitigate churn, and are there any pricing changes planned?
A:Efforts are focused on improving customer relationships and renewal rates. No significant pricing changes are planned, but modest step-ups are built into agreements.
Q:What is the market share growth outlook for the next year?
A:The focus is on returning to revenue growth rather than market share expansion. The company is addressing foundational issues to improve renewal rates and long-term growth.
Q:Review of Unclear Management Responses
A:Management avoided directly addressing the specific range of possibilities for renewals in December and January, providing general commentary on efforts and challenges instead. Additionally, they did not provide clear guidance on the mix of new customer growth versus expansion within existing accounts for 2026.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
API integration
Affairs research
Agency support
Core win
DH campaign
DH level
DH leverage
Definitive Healthcare
Definitive ability
LiveRamp
activation campaign
agency
area investment
attention
audience
claim
contact
core
count enterprise
customer count
customer experience
device
figure
goal
hierarchy
highlight
hospital
improvement focus
line value
opinion leader
partnership
pillar focus
pillar integration
sale support
source
support product
team
validation
value solution
DH Transcript
Definitive Healthcare Corp. (DH) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call highlights strong financial performance with a 15% revenue increase and improved net income, suggesting positive operational efficiencies. Despite macroeconomic risks and competitive challenges, the company's successful upselling and cost management efforts are promising. The lack of new strategic initiatives or return plans discussed may limit the upside, but the overall sentiment is positive due to the robust financial results.
Definitive Healthcare Corp. (DH) Q4 2025 Earnings Call Transcript
Unknown2-27
The earnings call presents mixed signals: modest improvements in renewal rates, strong professional services revenue growth, and positive AI integration are offset by declining revenue, operating cash flows, and net dollar retention. The Q&A indicates cautious optimism with unresolved management responses. The strategic focus on AI and product innovation offers potential, but the lack of clear guidance and revenue decline tempers expectations. Overall, the sentiment is balanced, suggesting a neutral stock price movement.
Definitive Healthcare Corp. (DH) Q3 2025 Earnings Call Transcript
Unknown11-6
Despite some positive indicators like increased operating cash flows and improved renewal rates, the overall sentiment is negative due to declining revenue guidance, subscription revenue decline, and management's vague responses on critical renewal issues. The Q&A highlighted budget constraints, particularly in life sciences, and expected gross margin pressure. These factors suggest a challenging environment, likely leading to a negative stock price reaction.
Definitive Healthcare Corp. (DH) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Neutral9-9
DH Slides
Definitive Healthcare Q4 2025 slides: profit gains amid revenue decline2026-02-26
Definitive Healthcare Q3 2025 slides: Revenue decline continues despite earnings beat2025-11-06
Definitive Healthcare Q2 2025 slides: revenue decline continues but exceeds guidance2025-08-07
Definitive Healthcare Q1 2025 slides: revenue declines 7% YoY, beats guidance2025-05-08
DH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
